CNBC Fast Money

2026-05-15 · Hosted by Melissa Lee · CNBC

Executive Summary

The trading desk dissected a euphoric session: Cerebras closed +68% at ~$311 in the largest semiconductor IPO ever; Dow reclaimed 50,000, S&P closed above 7,500 for the first time, Nasdaq at record highs. Nvidia added a 7-day winning streak with a market cap above $5.7 trillion, and Cisco had its best day in 15 years. Multiple guests cautioned that day-one Cerebras buyers above $300 may be left holding the bag, comparing the pattern to Figma, Clarna, and CoreWeave. Trump’s China visit produced a 200-jet Boeing commitment (vs. expected 500) but no breakthrough on Taiwan. The Senate Banking Committee advanced the bipartisan Clarity Act for crypto regulation.

Key Stories & Changes

1. Cerebras Debut — The Biggest Tech IPO of 2026

  • Priced $185, opened at $350, intraday peak $385, closed +68% at ~$311

  • Largest US tech IPO since Snowflake; largest semiconductor IPO ever

  • Fully diluted valuation ~$117 billion at peak, 228x last year’s $510M revenue

  • Backlog: $24.5 billion, with $20 billion from OpenAI alone

  • Morgan Stanley estimates ~$15 billion in revenue over next 3 years (vs. $510M in 2025)

  • Three customer buckets: labs (OpenAI), nations (UAE), cloud (AWS, terms TBD)

  • Gil Luria (DA Davidson, not yet covering): fair value ~$115/share (1x backlog), bull case = “Bugatti for inference,” bear case = “Concorde — niche too small”

  • Tiger Global made ~$1 billion in 7 months on its position

2. Earnings & After-Hours Movers

  • CRBS: Cerebras — +68% — Biggest tech IPO of year; OpenAI/AWS/UAE concentration

  • AMAT: Applied Materials — Higher AH — Record top/bottom; sees multi-year revenue/profit growth on AI boom

  • FIG: Figma — +9% AH — Beat earnings/revenue, raised guidance

  • NVDA: Nvidia — +4% — Market cap >$5.7T; 7-day winning streak

  • CSCO: Cisco — +15% — Best day in 15 years on AI infrastructure demand

  • BIIB: Biogen — -6% — Phase 2 Alzheimer’s missed primary endpoint, advancing to Phase 3 anyway

3. Biogen Alzheimer’s Trial Whipsaw

  • Stock initially +10%, closed down 6%

  • Phase 2 trial missed primary goal of dose-response, but Biogen says lower dose showed cognitive benefit and reduced tau protein

  • Tim Seymour: trades 11x next year, multiple viable drugs; selloff overdone

  • Carter Worth: bullish-to-bullish reversal pattern, headed higher

4. Trump-Xi Summit

  • Trump claims China agreed to buy 200 Boeing jets (down from 500 expected)

  • Xi pledged no military equipment to Iran, but China continues buying Iranian oil

  • Xi warned Trump that mishandling Taiwan could trigger “collision or conflict”

  • US readout omitted Taiwan; Trump declined to answer reporter questions on Taiwan

  • 90% of world’s chips produced in Taiwan — leverage clearly Xi’s, not Trump’s

5. Ford Energy Hype

  • Ford +20% over two days on Ford Energy launch and CATL battery partnership

  • Morgan Stanley applied 17.5x multiple on a $10B EV storage business

  • Tim Seymour: prefers GM (six times forward earnings, never been more profitable)

  • Carter Worth: F-150 EB was “most exciting car in EV market”

6. Crypto Clarity Act Advances

  • Senate Banking Committee approved on bipartisan basis

  • Allows rewards for using/spending stablecoins, not for holding them

  • Banks warn of loopholes; lobbying battle continues

  • Coinbase, Robinhood rallied; Bitcoin nearing $82K

  • Tim Seymour: prefers Coinbase over Bitcoin if directional bullish

7. China Internet Trade

  • KWEB (China internet ETF) had its worst day of the year, -4%

  • Carter Worth: time to buy — 36% drawdown, 52-week lows, asymmetrical setup

  • Multiple line-drawing techniques (downtrend, ascending triangle, wedge) all suggest reversal

8. Software Bounce

  • IGV up 2% today, +20% off April $74 low (now ~$90)

  • ServiceNow and “MicroStrategy” (Strategy) outperforming

  • Carter Worth: classic bearish-to-bullish reversal in IGV

  • Stuart Kaiser (Citi): cautious — needs sentiment shift, biggest short on price momentum

9. Mark Jacobs Sale

  • LVMH selling Mark Jacobs to brand management firm WHP Global, ending nearly 30-year partnership

  • Mark Jacobs remains creative director; deal terms undisclosed

  • Will push WHP global retail sales above $9.5 billion alongside Vera Wang and Rag & Bone

1. The Bagholder Pattern in 2026 IPOs

The desk explicitly flagged a recurring pattern: Figma, eToro, Clarna, CoreWeave all peaked on day one or two after IPO. Cerebras’s intraday peak above $385 fits the template. Tim Seymour predicted Cerebras could trade back at IPO price within 3 weeks — a structural caution about hot AI debuts when day-one demand becomes day-three supply.

2. Memory as the Tightest AI Bottleneck

Multiple panelists agreed memory is the most constrained input — Samsung and SK Hynix have indicated no new supply until end of 2026. This drives both micron’s appeal at 8x earnings and Cerebras’s value proposition (memory on the wafer eliminates KV cache shuttling). Stuart Kaiser (Citi) cited memory as Goldman’s “tightest bottleneck.”

3. AI as the Only Trade

Multiple references to AI being effectively the entire market story. Even traditionally non-tech names (Ford via Ford Energy) are getting bid because investors are looking for “the next data center play” and stumbling onto adjacent businesses.

4. Taiwan as China’s Trump Card

The asymmetry of leverage was repeatedly noted: with TSMC producing 90% of advanced chips, China holds the strategic card on Taiwan, not the US. The US cannot allow Chinese control of Taiwanese fabs, but the market hasn’t priced in this binary risk.

5. Concorde vs Bugatti Framing for AI Chips

DA Davidson’s Gil Luria framed the Cerebras debate as Bugatti (premium speed niche) vs. Concorde (too narrow to scale). The framework applies broadly to AI hardware: which companies have a real moat versus which are over-extrapolating a temporary memory tightness? —-

Sentiment Analysis

Overall Market Sentiment: Euphoric, Cautious Underneath

Records across major indices and historic IPO debut, but the desk consistently flagged valuation, concentration, and technical concerns about retail buyers entering at the top.

Risk Factors Highlighted

Cerebras lock-up & dilution: 84M shares unlock end of August, 80M more in September

OpenAI execution risk on $20B contract: Cerebras 86% concentrated in two UAE customers last year

Vera Rubin competition: Nvidia’s next chip closes the speed gap

Day-one Cerebras buyers: Pattern from Figma/Clarna/CoreWeave suggests near-term downside

Memory price reversal: Cerebras advantage partially predicated on current memory tightness

Taiwan blockade scenario: Could blow up the entire AI complex

Iran/Strait of Hormuz: Oil priced at $100/bbl; Trump-Xi deal vague on real cooperation

Boeing disappointment: 200 jets vs. expected 500 — incremental but underwhelming

Software sentiment: Biggest short on price momentum, requires sentiment shift to break out

Biotech failure pattern: Biogen’s history (adu-helm) makes investors skeptical of Phase 2-to-3 messaging

This episode was covered in today’s The Market Signal — 2026-05-15, a cross-source synthesis of multiple podcast reports.

Keep Reading